RMC No. 62-2025 updates VAT-exempt medicines for key diseases, requiring pharmacies and healthcare sellers to verify FDA publication and product tax codes.

Pharmacies, hospitals, clinics, distributors, importers, and VAT-registered sellers of covered medicines must immediately check the latest FDA-published VAT-exempt medicines list before issuing invoices, pricing products, or claiming VAT treatment. RMC No. 62-2025 confirms that the VAT exemption list for medicines has been updated through the Food and Drug Administration endorsement dated May 15, 2025, with both inclusions and deletions affecting the tax treatment of certain medicines.

What RMC No. 62-2025 Changes

RMC No. 62-2025 publishes the full text of the May 15, 2025 letter from the Food and Drug Administration of the Department of Health endorsing updates to the List of VAT-Exempt Products under Republic Act No. 10963, also known as the TRAIN Law, and Republic Act No. 11534, also known as the CREATE Act.

The most important compliance point is that the list of VAT-exempt medicines has changed. The update covers the inclusion of certain medicines for cancer, diabetes, high cholesterol, hypertension, mental illnesses, and tuberculosis. It also covers the deletion of a certain medicine for cancer.

For businesses in the pharmaceutical, healthcare, and medical supply chain, this is not merely a documentary update. The VAT treatment of a medicine directly affects selling price, billing, accounting entries, invoicing, tax returns, input VAT treatment, and customer-facing pricing. A product that appears on the updated VAT-exempt list should not be treated the same way as an ordinary VATable sale. Conversely, a medicine deleted from the list should not continue to be treated as VAT-exempt merely because it was previously covered.

Who Is Most Affected

The taxpayers most affected by RMC No. 62-2025 are VAT-registered drugstores, pharmacies, hospitals, clinics, health facilities, pharmaceutical importers, pharmaceutical distributors, wholesalers, retailers, and corporate accounting teams responsible for VAT coding of medical products.

The circular is also highly relevant to CFOs, controllers, tax managers, and in-house counsel of companies selling or reimbursing medicines for cancer, diabetes, high cholesterol, hypertension, mental illnesses, and tuberculosis. These are product categories that often involve high transaction volumes, sensitive patient pricing, and recurring purchases. A wrong VAT classification may affect not only tax compliance but also consumer pricing, reimbursement arrangements, and internal audit findings.

Businesses that maintain point-of-sale systems, enterprise resource planning systems, product master files, inventory codes, tax matrices, and billing templates should treat this issuance as a trigger to review their VAT setup. The search phrases many affected taxpayers will use include RMC 62-2025 VAT-exempt medicines, FDA VAT exempt medicine list 2025, CREATE Act VAT exemption medicines, TRAIN Law VAT exempt drugs, and VAT exemption cancer diabetes hypertension medicines Philippines.

Key Compliance Requirement: Check the FDA-Published Updates

RMC No. 62-2025 states that the attached May 15, 2025 FDA letter endorsed updates to the published list of VAT-exempt medicines. The BIR identifies two categories of changes: first, the inclusion of certain medicines for cancer, diabetes, high cholesterol, hypertension, mental illnesses, and tuberculosis; and second, the deletion of a certain medicine for cancer.

The practical compliance requirement is straightforward: taxpayers should not rely solely on old internal lists, outdated product tax codes, prior supplier representations, or previous VAT treatment. They must verify whether a medicine is included in, or deleted from, the updated FDA-published list before applying VAT exemption.

The circular does not provide a new VAT rate because the legal issue is exemption from VAT for covered products. It also does not announce a new filing form, separate registration step, or special BIR application procedure for taxpayers selling these products. Instead, the operational burden falls on the taxpayer to correctly identify which medicines are covered by the FDA update and to apply the correct VAT treatment in sales, invoicing, and reporting.

Effective Date and Timing

RMC No. 62-2025 is dated June 20, 2025. However, for the actual VAT exemption of the covered medicines and medical devices under the CREATE Act, the circular expressly refers to the rule clarified in Q&A No. 1 of RMC No. 99-2021: the effectivity of the VAT exemption is on the date of publication by the FDA of the updates to the list.

This means businesses must look at the FDA publication date of the specific update, not merely the BIR circular date, when determining when the VAT exemption applies. This is particularly important for transactions made close to the update period, where the timing of sale, invoice issuance, and system updates may affect whether VAT was properly imposed or removed.

For accounting teams, the urgent task is to determine the FDA publication date applicable to the updated list and align the tax treatment of affected stock keeping units from that date. For legal and tax teams, the task is to document the basis for VAT exemption, especially for high-value or high-volume medicines.

Penalties and Exposure for Non-Compliance

RMC No. 62-2025 does not prescribe a new penalty schedule, new surcharge, new interest rate, or special administrative fine for failure to follow the updated list. The circular is an information and guidance issuance that publishes the FDA-endorsed updates and reminds concerned taxpayers of the effectivity rule for VAT exemption.

That said, incorrect VAT treatment can still create tax exposure. If a taxpayer continues to impose VAT on medicines that are already covered by the FDA-published VAT-exempt list, it may face customer complaints, pricing disputes, refund issues, and accounting corrections. If a taxpayer treats a product as VAT-exempt even though it has been deleted from the list or is not covered by the update, the business may have underdeclared output VAT and may need to correct its VAT reporting.

The safest approach is to maintain a defensible audit trail showing the product name, FDA-published VAT-exempt status, date of FDA publication, internal tax code update, and the date when the pricing or invoicing system was changed.

Practical Steps for Businesses

First, identify all medicines in inventory or in the product master file that relate to cancer, diabetes, high cholesterol, hypertension, mental illnesses, and tuberculosis. These are the product categories expressly mentioned in RMC No. 62-2025.

Second, compare those products against the updated FDA-published list of VAT-exempt products. Pay particular attention not only to newly included medicines but also to the medicine for cancer that was deleted from the list. Deletions are a common source of tax leakage because old VAT-exempt coding may remain in the sales system long after a product is no longer covered.

Third, update point-of-sale systems, invoicing templates, product tax codes, ERP settings, and price lists. The VAT treatment should be aligned with the FDA publication date of the relevant update, consistent with the effectivity rule reiterated in RMC No. 62-2025.

Fourth, coordinate with suppliers and distributors. A retailer should not rely blindly on supplier invoices if its own sales system still applies a different VAT treatment. Businesses should ask for clear product-level documentation, especially for medicines falling within the affected categories.

Fifth, review VAT returns and sales records for transactions around the effective date. Where the wrong VAT treatment was applied, the company should assess whether accounting corrections, customer adjustments, or tax return amendments are necessary.

How Ablola, Saribong & Gueco Can Help

RMC No. 62-2025 is a reminder that VAT compliance for pharmaceutical and healthcare businesses depends on product-level accuracy, not general assumptions. A medicine may be VAT-exempt today, taxable tomorrow, or newly exempt depending on FDA publication and BIR guidance.

Ablola, Saribong & Gueco assists pharmacies, distributors, healthcare companies, hospitals, clinics, and corporate taxpayers in reviewing VAT treatment, updating compliance procedures, assessing exposure from incorrect VAT classification, and preparing defensible tax documentation. For guidance on RMC No. 62-2025, VAT-exempt medicines, CREATE Act VAT compliance, and BIR audit readiness, contact Ablola, Saribong & Gueco through MakatiLawFirm.com.


Leave a Comment

Your email address will not be published. Required fields are marked *